Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

APVOBearishIndustry Newsnews

High materiality7/10

APVO's mipletamig triplet yields 93% benefit in TP53-mutant AML

Sep 3, 2026, 3:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite positive efficacy, APVO sold off ~22%, suggesting the market remains cautious about near-term catalysts and the path to multi-dose phase 3, amid funding/valuation concerns.

AI summary

What happened, with direct paths to the underlying reporting

Aptevo disclosed that mipletamig, used with venetoclax and azacitidine, achieved a 93% clinical benefit rate in frontline TP53-mutated AML. In 13 of 14 evaluable patients, 11 reached remission, including nine full CRs. The RAINIER program targets dose optimization by year-end with 2027 regulatory discussions, signaling a potential late-stage catalyst if efficacy persists.

APVO reports 93% clinical benefit for mipletamig triplet in TP53-mutated AML.
11/14 evaluable patients achieved CR or CRi; 9 reached full CR.
Triplet results exceed 41% remission with venetoclax/azacitidine in similar patients.
RAINIER Phase 1b/2 aims to finish dose optimization by year-end; regulatory talks in 1H2027.
Shares fell ~22% to $2.02 after the update.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.